% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kuznia:182558,
      author       = {S. Kuznia$^*$ and D. Czock and A. Kopp-Schneider$^*$ and R.
                      Caspari and H. Fischer and D. C. Laetsch and M. Slavic$^*$
                      and H. Brenner$^*$ and B. Schöttker$^*$},
      title        = {{E}fficacy and {S}afety of a {P}ersonalized {V}itamin {D}3
                      {L}oading {D}ose {F}ollowed by {D}aily 2000 {IU} in
                      {C}olorectal {C}ancer {P}atients with {V}itamin {D}
                      {I}nsufficiency: {I}nterim {A}nalysis of a {R}andomized
                      {C}ontrolled {T}rial.},
      journal      = {Nutrients},
      volume       = {14},
      number       = {21},
      issn         = {2072-6643},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2022-02739},
      pages        = {4546},
      year         = {2022},
      note         = {#EA:C070#LA:C070#LA:C120#},
      abstract     = {A personalized vitamin D3 loading dose has not yet been
                      tested in cancer patients. This interim analysis of the
                      randomized, placebo-controlled VICTORIA trial analyzed the
                      first recruited 74 German adults with nonmetastatic
                      colorectal cancer, a tumor surgery within the past year, and
                      25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study
                      participants received a loading dose tailored for a baseline
                      25(OH)D level and BMI in the first 11 days, followed by a
                      maintenance dose of 2000 IU of vitamin D3 daily until end of
                      trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and
                      34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5
                      nmol/L in the verum group during screening, visit 1 (end of
                      loading dose), and visit 2 (end of maintenance dose),
                      respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at
                      visits 1 and 2 was $3.5\%$ and $17.4\%$ in the placebo group
                      and $80.0\%$ and $100\%$ in the verum group. No events of
                      25(OH)D > 150 nmol/L or hypercalcemia were observed.
                      Hypercalciuria events at visit 1 (n = 5 in verum and n = 1
                      in the placebo group; p = 0.209) receded after
                      discontinuation of the study medication. The personalized
                      loading dose effectively and safely increased the 25(OH)D
                      levels, and 2000 IU of vitamin D3 daily sustained the
                      achieved levels.},
      keywords     = {bolus (Other) / calcium (Other) / colorectal cancer (Other)
                      / efficacy (Other) / loading dose (Other) / personalized
                      medicine (Other) / randomized controlled trial (Other) /
                      safety (Other) / treatment regimen (Other) / vitamin D
                      (Other)},
      cin          = {C070 / C120 / HD01 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
                      I:(DE-He78)HD01-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36364809},
      doi          = {10.3390/nu14214546},
      url          = {https://inrepo02.dkfz.de/record/182558},
}